Circle K Triple Antibiotic Ointment Recalled Over Manufacturing Deficiencies
The FDA listed a recall for Circle K triple antibiotic ointment in 0.5-ounce (14.2-gram) tubes on June 2, 2026. The recall cites cGMP deviations and deficiencies observed during an FDA inspection.
What matters now
- The recall covers Circle K triple antibiotic ointment in 0.5-ounce (14.2-gram) tubes.
- The listed strengths are bacitracin zinc 400 units, neomycin sulfate 3.5 mg, and Polymyxin-B sulfate 5,000 units.
- The recall reason is cGMP deviations and deficiencies observed during an FDA inspection.
- The exact product should be compared with the current FDA record.
Which ointment is affected
The affected product is Circle K triple antibiotic ointment in 0.5-ounce (14.2-gram) tubes. The listed active ingredients are bacitracin zinc 400 units, neomycin sulfate 3.5 mg, and Polymyxin-B sulfate 5,000 units. The FDA record’s brand field lists dabur india limited.
Why the ointment was recalled
The FDA lists cGMP deviations and deficiencies observed during an agency inspection as the recall reason.
How to check your ointment
Compare the product name, tube size, active ingredients, and strengths with the current FDA recall record. Use that official record to confirm whether an exact product is affected.
Action